Non-Hodgkin's Lymphoma

Oncology
49
Pipeline Programs
22
Companies
40
Clinical Trials
2 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
13
15
10
0
4
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1179%
Small Molecule
321%
+ 33 programs with unclassified modality

On Market (3)

Approved therapies currently available

U
BENDAMUSTINE HYDROCHLORIDEApproved
bendamustine hcl
Unknown Company
intravenous2023
U
VALSARTANApproved
valsartan
Unknown Company
Angiotensin 2 Receptor Blocker [EPC]oral2018
U
VEPESIDApproved
etoposide
Unknown Company
oral1986

Competitive Landscape

22 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
5 programs
2
1
1
rituximabPhase 4Monoclonal Antibody1 trial
ZevalinPhase 31 trial
IDEC-114Phase 1/21 trial
IDEC-114Phase 1/21 trial
RituximabN/AMonoclonal Antibody1 trial
Active Trials
NCT00387023Completed12Est. Jul 2012
NCT00048555Completed90Est. Nov 2010
NCT00575068Completed42Est. Nov 2010
+2 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
1
1
ValsartanPhase 4Small Molecule1 trial
EtoposidePhase 31 trial
Active Trials
NCT06520163RecruitingEst. Aug 2026
NCT00162955CompletedEst. Sep 2010
Sanofi
SanofiPARIS, France
1 program
1
Granulocyte-colony stimulating factorPhase 41 trial
Active Trials
NCT01164475Completed61Est. Feb 2013
Swedish Orphan Biovitrum
1 program
1
KepivancePhase 41 trial
Active Trials
NCT00352703CompletedEst. May 2007
Teva
TevaIsrael - Petach Tikva
3 programs
1
2
BendamustinePhase 31 trial
Bendamustine HClPhase 31 trial
SDX-105Phase 21 trial
Active Trials
NCT00069758Completed72Est. Apr 2007
NCT01073163Completed54Est. Jun 2012
NCT00139841Completed103Est. Oct 2009
Genentech
GenentechCA - Oceanside
5 programs
3
2
PRO95780Phase 21 trial
RituximabPhase 2Monoclonal Antibody1 trial
ABT-199Phase 1
ABT-199Phase 1
rituximabPhase 1Monoclonal Antibody
Active Trials
NCT00517049Completed49Est. Dec 2009
NCT00809341Terminated27Est. Apr 2014
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
ZevalinPhase 21 trial
CHOPPhase 11 trial
Active Trials
NCT00323323Completed24Est. Oct 2016
NCT00220285Completed45Est. Oct 2005
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
2
TopotecanPhase 22 trials
epratuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00113789Completed21Est. Apr 2005
NCT00100477Completed10Est. Jun 2001
NCT00044902Completed
E
EisaiChina - Liaoning
1 program
1
ONTAKPhase 21 trial
Active Trials
NCT00051025Completed9Est. Sep 2006
Dynavax Technologies
Dynavax TechnologiesCA - Emeryville
1 program
1
RituxanPhase 21 trial
Active Trials
NCT00251394Completed30Est. Jul 2009
Alliance Pharmaceuticals
1 program
1
VincristinePhase 21 trial
Active Trials
NCT00250718Terminated17Est. May 2014
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
bevacizumab, RituximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00788606Terminated7Est. Jun 2010
GS
Gilead SciencesFOSTER CITY, CA
11 programs
4
7
GS-9219Phase 1/21 trial
GS-9219Phase 1/2
hA20-humanized anti-CD20 antibodyPhase 1/2
hA20-humanized anti-CD20 antibodyPhase 1/21 trial
hLL1-DOXPhase 1/21 trial
+6 more programs
Active Trials
NCT01728207Terminated30Est. Mar 2017
NCT00504972Completed23Est. Oct 2015
NCT00499239Terminated32Est. Oct 2010
+3 more trials
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
2 programs
1
1
ChiauranibPhase 1/2Small Molecule1 trial
ChiauranibPhase 1Small Molecule1 trial
Active Trials
NCT03074825TerminatedEst. Feb 2019
NCT03974243CompletedEst. Dec 2021
Novartis
NovartisBASEL, Switzerland
1 program
1
HCD122Phase 1/21 trial
Active Trials
NCT00670592Completed111Est. Feb 2013
Celldex Therapeutics
1 program
1
PembrolizumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT03789097Unknown56Est. Mar 2025
Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
1 program
1
SB-743921Phase 1/21 trial
Active Trials
NCT00343564Completed68Est. Jul 2010
CT
1 program
1
TQB2303Phase 1/21 trial
Active Trials
NCT03456466UnknownEst. Jun 2018
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
Vincristine Sulfate Liposome Injection plus rituximabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT01851551CompletedEst. Apr 2005
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
2
ABBV-291Phase 11 trial
ABT-199Phase 11 trial
Active Trials
NCT06667687Recruiting165Est. Nov 2031
NCT01969695Completed11Est. Dec 2019
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
1
TGR-1202Phase 11 trial
Active Trials
NCT01767766Completed90Est. Feb 2018
Pfizer
PfizerNEW YORK, NY
1 program
1
rituximabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00556699Completed22Est. Nov 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SanofiGranulocyte-colony stimulating factor
Swedish Orphan BiovitrumKepivance
City TherapeuticsValsartan
Biogenrituximab
City TherapeuticsEtoposide
TevaBendamustine
TevaBendamustine HCl
BiogenZevalin
GenentechRituximab
Rochebevacizumab, Rituximab
GenentechPRO95780
Alliance PharmaceuticalsVincristine
BayerZevalin
Dynavax TechnologiesRituxan
AmgenTopotecan

Showing 15 of 39 trials with date data

Clinical Trials (40)

Total enrollment: 1,983 patients across 40 trials

NCT01164475SanofiGranulocyte-colony stimulating factor

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Start: Oct 2010Est. completion: Feb 201361 patients
Phase 4Completed
NCT00352703Swedish Orphan BiovitrumKepivance

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

Start: Apr 2006Est. completion: May 2007
Phase 4Completed
NCT00162955City TherapeuticsValsartan

Prevention of CHOP-induced Chronic Cardiotoxicity

Start: May 2004Est. completion: Sep 2010
Phase 4Completed
NCT00090038Biogenrituximab

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Start: Oct 2003Est. completion: Nov 2007168 patients
Phase 4Completed
NCT06520163City TherapeuticsEtoposide

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Start: Aug 2024Est. completion: Aug 2026
Phase 3Recruiting
NCT01073163TevaBendamustine

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Start: Feb 2010Est. completion: Jun 201254 patients
Phase 3Completed
NCT00139841TevaBendamustine HCl

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

Start: Oct 2005Est. completion: Oct 2009103 patients
Phase 3Completed
NCT00057343BiogenZevalin

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Start: Mar 2003400 patients
Phase 3Terminated
NCT00044902Amgenepratuzumab

Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

Phase 2Completed
NCT00809341GenentechRituximab

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Start: Jan 2009Est. completion: Apr 201427 patients
Phase 2Terminated
NCT00788606Rochebevacizumab, Rituximab

R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

Start: May 2008Est. completion: Jun 20107 patients
Phase 2Terminated
NCT00517049GenentechPRO95780

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Start: Mar 2008Est. completion: Dec 200949 patients
Phase 2Completed
NCT00250718Alliance PharmaceuticalsVincristine

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Start: Oct 2004Est. completion: May 201417 patients
Phase 2Terminated
NCT00220285BayerZevalin

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Start: Aug 2004Est. completion: Oct 200545 patients
Phase 2Completed
NCT00251394Dynavax TechnologiesRituxan

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Start: Jul 2004Est. completion: Jul 200930 patients
Phase 2Completed
NCT00113789AmgenTopotecan

Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer

Start: Oct 2003Est. completion: Apr 200521 patients
Phase 2Completed
NCT00069758TevaSDX-105

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

Start: Sep 2003Est. completion: Apr 200772 patients
Phase 2Completed
NCT00051025EisaiONTAK

Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

Start: May 2000Est. completion: Sep 20069 patients
Phase 2Completed
NCT00100477AmgenTopotecan

Use of Topotecan in Patients With Refractory Acute Leukemia

Start: Aug 1998Est. completion: Jun 200110 patients
Phase 2Completed
NCT03974243Chipscreen BiosciencesChiauranib

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Start: Jul 2019Est. completion: Dec 2021
Phase 1/2Completed
NCT03789097Celldex TherapeuticsPembrolizumab

Vaccination With Flt3L, Radiation, and Poly-ICLC

Start: Apr 2019Est. completion: Mar 202556 patients
Phase 1/2Unknown
NCT03456466Chia Tai TianQing Pharmaceutical GroupTQB2303

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Start: May 2017Est. completion: Jun 2018
Phase 1/2Unknown
NCT01585688Gilead ScienceshLL1-DOX

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Start: Aug 2012Est. completion: Oct 201713 patients
Phase 1/2Terminated
NCT00670592NovartisHCD122

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Start: Mar 2008Est. completion: Feb 2013111 patients
Phase 1/2Completed
NCT00499239Gilead SciencesGS-9219

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Start: Jul 2007Est. completion: Oct 201032 patients
Phase 1/2Terminated
NCT00343564CytokineticsSB-743921

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Start: Apr 2006Est. completion: Jul 201068 patients
Phase 1/2Completed
NCT00285428Gilead ScienceshA20-humanized anti-CD20 antibody

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Start: Sep 2004Est. completion: Oct 200782 patients
Phase 1/2Completed
NCT00596804Gilead Sciencesveltuzumab

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Start: Mar 2004Est. completion: Nov 200739 patients
Phase 1/2Completed
NCT00048555BiogenIDEC-114

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Start: Nov 2002Est. completion: Nov 201090 patients
Phase 1/2Completed
NCT00575068BiogenIDEC-114

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Start: Jan 2002Est. completion: Nov 201042 patients
Phase 1/2Completed
NCT01851551Acrotech BiopharmaVincristine Sulfate Liposome Injection plus rituximab

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Start: Sep 2001Est. completion: Apr 2005
Phase 1/2Completed
NCT06667687AbbVieABBV-291

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Start: Jan 2025Est. completion: Nov 2031165 patients
Phase 1Recruiting
NCT03074825Chipscreen BiosciencesChiauranib

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Start: May 2017Est. completion: Feb 2019
Phase 1Terminated
NCT01969695AbbVieABT-199

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Start: Dec 2013Est. completion: Dec 201911 patients
Phase 1Completed
NCT01728207Gilead SciencesIMMU-114

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Start: Mar 2013Est. completion: Mar 201730 patients
Phase 1Terminated
NCT01767766TG TherapeuticsTGR-1202

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Start: Jan 2013Est. completion: Feb 201890 patients
Phase 1Completed
NCT00556699Pfizerrituximab

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Start: Dec 2007Est. completion: Nov 201022 patients
Phase 1Completed
NCT00504972Gilead ScienceshLL1

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

Start: Jun 2007Est. completion: Oct 201523 patients
Phase 1Completed
NCT00323323BayerCHOP

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Start: Mar 2004Est. completion: Oct 201624 patients
Phase 1Completed
NCT00387023BiogenRituximab

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

Start: Feb 2004Est. completion: Jul 201212 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,983 patients
22 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)